Last reviewed · How we verify
RP-6306
At a glance
| Generic name | RP-6306 |
|---|---|
| Also known as | Lunresertib |
| Sponsor | Canadian Cancer Trials Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer (PHASE2)
- RP-6306 in Patients With Advanced Cancer (PHASE2)
- Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer (PHASE1)
- Study of RP-6306 With FOLFIRI in Advanced Solid Tumors (PHASE1)
- Study of RP-6306 With Gemcitabine in Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |